Compare Abbott Laboratories (ABT) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs UnitedHealth Group Inc — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while UnitedHealth Group Inc trades at $424.95 (market cap $388.86B). The key difference: UnitedHealth Group Inc is far larger — about 2.3× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | UNH | |
|---|---|---|
Market Cap | $166.94B | $388.86B |
Sector | Health | Health |
52-Week High | $136.62 | $428.19 |
52-Week Low | $82.57 | $237.77 |
Enterprise Value | $193.69B | $435.55B |
Dividend Yield | 2.63% | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
UnitedHealth Group (UNH) trades at $425.60, up 1.82% today, with strong technical momentum and bullish moving average signals. The company reported Q1 2026 EPS of $7.23, beating expectations, while revenue reached $447.57B in 2025. Analyst consensus remains overwhelmingly positive with 82.7% buy ratings and a $419.47 price target. Recent news highlights operational improvements, including reduced pediatric prior authorizations and continued dividend growth.
UNH presents a compelling investment case driven by consistent earnings beats, robust cash flow generation, and strategic initiatives to streamline healthcare operations. Key risks include regulatory scrutiny from recent lawsuits and Medicaid fraud allegations, alongside margin pressure from rising medical costs. The stock's current valuation at 32.24x P/E requires sustained execution to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
